TREM2 and neoplasm: New functional biomarkers, including TREM2, MARCO, SPP1, C1QC, SIGLEC1, SIGLEC10, DC-SIGN, APOC1, CTSB, GPNMB, FOLR2 and others, annotated with immunosuppression, lipid metabolism, scavenging, antigen presentation, glycolysis, angiogenesis, hypoxia, and tumor cell invasion, have been defined for TAMs in different cancers [37].